Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Kimmtrak (tebentafusp-tebn)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Immunocore, Medison

Drug class:

CD3 agonist, gp100 inhibitor

Related drugs:

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

›

HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1	tebentafusp-tebn Sensitive: A1 - Approval tebentafusp-tebn Sensitive : A1
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2	ipilimumab + tebentafusp-tebn Sensitive: A2 - Guideline ipilimumab + tebentafusp-tebn Sensitive : A2
CXCL10 elevation	Uveal Melanoma	CXCL10 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
CXCL10 elevation	Cutaneous Melanoma	CXCL10 elevation	Cutaneous Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
IL6 elevation	Uveal Melanoma	IL6 elevation	Uveal Melanoma	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3	tebentafusp-tebn Sensitive: C3 – Early Trials tebentafusp-tebn Sensitive : C3
HLA-A2 positive + PMEL overexpression	Melanoma	HLA-A2 positive + PMEL overexpression	Melanoma	durvalumab + tremelimumab-actl + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tremelimumab-actl + tebentafusp-tebn Sensitive : C3	durvalumab + tremelimumab-actl + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tremelimumab-actl + tebentafusp-tebn Sensitive : C3
HLA-A*02:01	Cutaneous Melanoma	HLA-A*02:01	Cutaneous Melanoma	durvalumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tebentafusp-tebn Sensitive : C3	durvalumab + tebentafusp-tebn Sensitive: C3 – Early Trials durvalumab + tebentafusp-tebn Sensitive : C3